Detail of "55508-42-4"

CAS Number:
55508-42-4
Name:
L-Leucine,5-oxo-L-prolyl-L-leucyl-L-tyrosyl-L-a-glutamyl-L-asparaginyl-L-lysyl-L-prolyl-L-arginyl-L-arginyl-L-prolyl-L-tyrosyl-L-isoleucyl-
Molecular Structure:
Formula:
C78H121 N21 O20
Molecular Weight:
1672.92
Synonyms:
Neurotensin(cattle) (9CI); Neurotensin (ox); 10: PN: WO2009140972 SEQID: 10 claimedprotein; 1: PN: WO2007100718 TABLE: 1 claimed protein; 1: PN: WO2009132656SEQID: 10 claimed protein; 29: PN: WO2007058336 SEQID: 29 claimed protein; 49:PN: WO0061194 SEQID: 49 claimed sequence; Bovine neurotensin; Canineneurotensin; Mouse neurotensin; Neurotensin (bovine hypothalamus); Neurotensin(dog); Neurotensin (rat); Neurotensin(1-13); Ox neurotensin

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Verification of both the sequence and conformational specificity of neurotensin in binding to mast cells: Verification of both the sequence and conformational specificity of neurotensin in binding to mast cells. Lazarus, L. H.; Perrin, M. H.; Brown, M. R.; Rivier, J. E. (Lab. Neuroendocrinol., Salk Inst., La Jolla, Calif., USA). Biochem. Biophys. Res. Commun., 76(4), 1079-85 (English) 1977. CODEN: BBRCA9. DOCUMENT TYPE: Journal CA Section: 2 (Hormone Pharmacology) Neurotensin (NT) [55508-42-4] analogs, modified at Arg8 and Arg9, were used to assess the role of Arg in NT binding to mast cells. [D-Arg8]-neurotensin [63770-61-6] and [D-Arg9]-neurotensin [63770-62-7] bound 4-5 times better than NT, whereas [D-Arg8,9]neurotensin [63770-63-8] had the same binding affinity as NT. Binding of [Ala8]-neurotensin [63817-74-3] was not parallel to NT and exhibited a dissocn. const. 38-fold lower than NT whereas [Ala9]-NT [63817-75-4] had 32% binding. C-terminal peptides, NT8-13 [60482-95-3] and NT9-13 [60482-96-4] had .apprx.65% binding. Apparently, Arg8 plays a greater role than Arg9 in the binding to mast cell NT receptors. Redn. of the disulfide bond in [Cys1,13]-NT [63770-65-0] produced an analog 4- times more potent than NT, while the cyclized form had only 3% binding. Thus, a linear peptide with a free C-terminus appears to be required for binding.

Neurotensin: central nervous system effects of a hypothalamic peptide: Neurotensin: central nervous system effects of a hypothalamic peptide. Nemeroff, Charles B.; Bissette, Garth; Prange, Arthur J., Jr.; Loosen, Peter T.; Barlow, T. Steven; Lipton, Morris A. (Biol. Sci. Res. Cent., Univ. North Carolina Sch. Med., Chapel Hill, N. C., USA). Brain Res., 128(3), 485-96 (English) 1977. CODEN: BRREAP. DOCUMENT TYPE: Journal CA Section: 2 (Hormone Pharmacology) Section cross-reference(s): 1 The central administration of neurotensin [55508-42-4], an endogenous hypothalamic tridecapeptide, produced a marked dose-related decrease in body temp. of mice and rats at an ambient temp. of 25.degree.. This effect was even more pronounced when mice were placed at 4.degree. to increase the rate of decline of body temp. Other sequelae obsd. after central administration of neurotensin were decreases in locomotor activity in rats and a marked dose-related enhancement in pentobarbital [57-33-0]-induced mortality, sedation, and hypothermia. This latter effect was due to a decrease in the metabolic degrdn. of the barbiturate. None of these effects were obsd. after peripheral neurotensin administration, suggesting that this peptide does not readily cross the blood-brain barrier. Neurotensin is apparently a neuropeptide that can affect central nervous system function.